InsidersTradesSigma
Track the MapLight Therapeutics, Inc. share price and the full directors' dealings record of the company, a listed issuer based in United States. Shares are quoted on the US market, under the authority of SEC (Form 4). Market capitalisation: €581.6m. The latest transaction was reported on 19 August 2026 (Attribution). Among the most active insiders: GILLIS JONATHAN. Every trade is openly available.
135
Insider Decl.
n/a
Thresholds
€57m
8 ops.
Buy Volume
€15m
76 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate MapLight Therapeutics, Inc. Strong Buy (bullish), based on 13 analysts. Average price target: US$26.69.
60Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 19 August 2026
Declarations135 total
13,360 shares0Voting Common StockSEC:0002021233-26-000014:0
6,020 shares0Voting Common StockSEC:0001709954-26-000012:0
2,222 shares0Voting Common StockSEC:0001709954-26-000012:1
7,730 shares0Voting Common StockSEC:0001789970-26-000014:0
6,020 shares0Voting Common StockSEC:0002021238-26-000012:0
23,145 shares0Voting Common StockSEC:0001658918-26-000016:0
7,730 shares0Voting Common StockSEC:0001728746-26-000016:0
4,400,000 shares@ US$11.389.63% mcap76.4% of flowVoting Common StockSEC:0001900201-26-000005:0
Canonical exit: 12 Nov 2026 (T+90)
22,082 shares@ US$12.540.047% mcap9.7% of flowVoting Common StockSEC:0001728746-26-000014:0
22,082 shares@ US$13.020.049% mcap11.1% of flowCommonSEC144:0001974158-26-000093
1,600,000 shares@ US$15.023.80% mcap100.0% of flowVoting Common StockSEC144:0001388325-26-000032
141,088 shares@ US$10.74160.24% mcap10.0% of flowVoting Common StockSEC:0001900201-26-000003:0
Canonical exit: 26 Oct 2026 (T+90)
65,137 shares@ US$11.68910.12% mcap5.0% of flowVoting Common StockSEC:0001900201-26-000003:1
Canonical exit: 26 Oct 2026 (T+90)
3,000 shares@ US$12.630.0060% mcap0.2% of flowVoting Common StockSEC:0001900201-26-000003:2
Canonical exit: 27 Oct 2026 (T+90)
1,000,000 shares@ US$13.002.05% mcap84.8% of flowVoting Common StockSEC:0001900201-26-000003:3
Canonical exit: 28 Oct 2026 (T+90)
4,699 shares@ US$36.940.034% mcap4.5% of flowVoting Common StockSEC:0001709954-26-000010:1
5,545 shares@ US$36.130.039% mcap5.8% of flowVoting Common StockSEC:0002021238-26-000010:0
900 shares@ US$38.170.0067% mcap0.9% of flowVoting Common StockSEC:0001709954-26-000010:6
5,356 shares@ US$36.130.038% mcap5.0% of flowVoting Common StockSEC:0001709954-26-000010:0
6,979 shares@ US$36.660.050% mcap6.6% of flowVoting Common StockSEC:0001709954-26-000010:2
1,476 shares@ US$37.440.011% mcap1.4% of flowVoting Common StockSEC:0001709954-26-000010:3
600 shares@ US$36.510.0043% mcap0.6% of flowVoting Common StockSEC:0001709954-26-000010:4
16,969 shares@ US$37.610.12% mcap16.4% of flowVoting Common StockSEC:0001709954-26-000010:5
7,464 shares@ US$36.660.053% mcap7.9% of flowVoting Common StockSEC:0002021238-26-000010:2
25 of 135 declarations
About MapLight Therapeutics, Inc.
MapLight Therapeutics, Inc. is a company focused on developing innovative therapies for the treatment of neurological diseases. It is listed on NASDAQ under the ticker XNAS.